Browse ANO1

Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Cytoplasm Note=Cytoplasmic localization seen in neoplastic cells of head and neck squamous cell carcinoma (HNSCC) tumors.
Domain PF16178 Dimerisation domain of Ca+-activated chloride-channel
PF04547 Calcium-activated chloride channel
Function

Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction. Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development.

> Gene Ontology
 
Biological Process GO:0001678 cellular glucose homeostasis
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0006820 anion transport
GO:0006821 chloride transport
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0009266 response to temperature stimulus
GO:0009306 protein secretion
GO:0009408 response to heat
GO:0009581 detection of external stimulus
GO:0009582 detection of abiotic stimulus
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015698 inorganic anion transport
GO:0015705 iodide transport
GO:0015833 peptide transport
GO:0016048 detection of temperature stimulus
GO:0019233 sensory perception of pain
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0032024 positive regulation of insulin secretion
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0034605 cellular response to heat
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0035773 insulin secretion involved in cellular response to glucose stimulus
GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0042593 glucose homeostasis
GO:0042886 amide transport
GO:0044070 regulation of anion transport
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0050951 sensory perception of temperature stimulus
GO:0050961 detection of temperature stimulus involved in sensory perception
GO:0050965 detection of temperature stimulus involved in sensory perception of pain
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0061178 regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
GO:1902476 chloride transmembrane transport
GO:1903532 positive regulation of secretion by cell
GO:1903959 regulation of anion transmembrane transport
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0005216 ion channel activity
GO:0005227 calcium activated cation channel activity
GO:0005229 intracellular calcium activated chloride channel activity
GO:0005244 voltage-gated ion channel activity
GO:0005247 voltage-gated chloride channel activity
GO:0005253 anion channel activity
GO:0005254 chloride channel activity
GO:0005261 cation channel activity
GO:0008308 voltage-gated anion channel activity
GO:0008509 anion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015108 chloride transmembrane transporter activity
GO:0015111 iodide transmembrane transporter activity
GO:0015267 channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022832 voltage-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022839 ion gated channel activity
GO:0061778 intracellular chloride channel activity
Cellular Component GO:0016324 apical plasma membrane
GO:0034702 ion channel complex
GO:0034707 chloride channel complex
GO:0045177 apical part of cell
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-983712: Ion channel transport
R-HSA-2672351: Stimuli-sensing channels
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ANO1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ANO1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ANO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3520.00117
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.4240.0341
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5590.491
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8060.104
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3020.549
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1730.953
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4920.387
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9780.42
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0670.96
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7180.586
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.2540.179
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4170.0179
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ANO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ANO1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ANO1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ANO1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ANO1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ANO1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ANO1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolANO1
Nameanoctamin 1, calcium activated chloride channel
Aliases TAOS2; FLJ10261; DOG1; ORAOV2; TMEM16A; oral cancer overexpressed 2; transmembrane protein 16A; Ca2+-activat ......
Chromosomal Location11q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ANO1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ANO1.
ID Name Drug Type Targets #Targets
DB04941CrofelemerSmall MoleculeANO1, CFTR2